TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Oblique Therapeutics AB (publ)
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 | 2022/12 (consolidated) |
| Turnover |
43
|
0
|
0 |
| Financial expenses |
6
|
5
|
183 |
| Earnings before taxes |
-2,555
|
-5,581
|
-4,812 |
| EBITDA |
-2,482
|
-3,403
|
-4,334 |
| Total assets |
1,492
|
1,673
|
1,633 |
| Current assets |
1,357
|
1,457
|
729 |
| Current liabilities |
443
|
552
|
1,012 |
| Equity capital |
976
|
1,044
|
302 |
| - share capital |
199
|
165
|
68 |
| Employees (average) |
10
|
18
|
18 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 (consolidated) |
| Solvency |
65.4%
|
62.4%
|
18.5% |
| Turnover per employee |
4
|
0
|
0 |
| Profit as a percentage of turnover | -5941.9% | ||
| Return on assets (ROA) |
-170.8%
|
-333.3%
|
-283.5% |
| Current ratio |
306.3%
|
263.9%
|
72.0% |
| Return on equity (ROE) |
-261.8%
|
-534.6%
|
-1593.4% |
| Change turnover |
43
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees |
-8
|
0
|
2 |
| Chg. No. of employees % | -44% | 13% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.